<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971659</url>
  </required_header>
  <id_info>
    <org_study_id>49/0316-Adjunct</org_study_id>
    <nct_id>NCT00971659</nct_id>
  </id_info>
  <brief_title>Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes</brief_title>
  <official_title>Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or
      a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and
      their effect on blood glucose control, versus insulin glargine alone as active comparator in
      type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the different mechanisms of action of the long-acting insulin analog insulin glargine
      and both a GLP-1 analog (exenatide) and a DPP-4-inhibitor (sitagliptin), it could be a
      promising approach to combine insulin glargine with either exenatide or sitagliptin for
      optimum control of fasting and postprandial blood glucose values. Thus, in the present study
      the influence of either exenatide or sitagliptin as a 4-week adjunctive therapy to a basal
      insulin (insulin glargine) was investigated versus insulin glargine alone as active
      comparator in subjects with type 2 diabetes. Preexisting metformin was continued,
      sulfonylureas, if any, were stopped. In particular, the effects on postprandial blood glucose
      excursion following ingestion of a standard breakfast, assessed after 4 weeks of treatment,
      the effects on mean daily blood glucose, on self-measured 7-point profiles, the percentage of
      subjects reaching ADA treatment goals (HbA1c &lt; 7.0%) at the end of treatment, on fasting
      lipid profile, on HOMA index, weight, hypoglycemic episodes and general safety were assessed.
      The study consisted of a screening visit, a 4-8 week (depending on pre-treatment) run-in
      period, a 4-week treatment period, and a follow-up visit. There were weekly visits at the
      site and twice weekly telephone contacts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>insulin glargine + exenatide + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine + sitagliptin + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin glargine + metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine + exenatide + preexisting metformin</intervention_name>
    <description>insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin</description>
    <arm_group_label>insulin glargine + exenatide + metformin</arm_group_label>
    <other_name>Lantus</other_name>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine + sitagliptin + preexisting metformin</intervention_name>
    <description>insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin</description>
    <arm_group_label>Insulin glargine + sitagliptin + metformin</arm_group_label>
    <other_name>Lantus</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine + preexisting metformin</intervention_name>
    <description>insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin</description>
    <arm_group_label>insulin glargine + metformin</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female subjects aged between 35 and 70 years, inclusive

          -  type 2 diabetes with duration &gt;6 months and &lt;10 years

          -  for at least 3 months: treatment solely with a long- or intermediate-acting insulin
             formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a
             stable dose of metformin or treatment solely with a stable dose of metformin or
             combination of stable doses of metformin plus sulfonylureas

          -  HbA1c &gt;=7.0% and &lt;=10.0%

          -  if treated with antihypertensive or lipid lowering agents, the treatment regimen had
             to be stable during 3 months prior to study start

          -  written informed consent

        Exclusion Criteria:

          -  history or presence of cancer or any clinically relevant diseases

          -  chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial
             infarction within the previous 6 months

          -  recurrent hypoglycemia

          -  abnormal lab tests at screening (ALAT and/or ASAT &gt;=3 times ULN), creatinine &gt;1.6
             mg/dL in males and &gt;1.4 mg/dL in females

          -  clinically relevant ECG findings at screening

          -  treatment with a rapid-acting insulin or with a mixed insulin formulation during the
             previous 3 months

          -  treatment with any other OHA than metformin or metformin plus sulfonylureas during the
             previous 3 months

          -  any systemic or topical treatment with drugs known to influence glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Arnolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>September 3, 2009</last_update_submitted>
  <last_update_submitted_qc>September 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christoph Kapitza, MD</name_title>
    <organization>Profil Institut für Stoffwechselforschung GmbH</organization>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

